WAT Medical / HeadaTerm

WAT Medical operates in the medical-device and personal-health categories, focusing on wearable electrical stimulation for nausea, migraine and related wellness needs. Its named products span several use cases: EmeTerm is a wearable anti-nausea wristband, HeadaTerm is a forehead-worn migraine device, and ObeEnd is a neuromodulation wristband positioned around weight management and exercise-related measures. The company’s stated differentiator is a drug-free, portable approach using non-invasive stimulation technologies, including TENS, TEAS and external trigeminal nerve stimulation. HeadaTerm 2’s inclusion in the American Migraine Foundation’s Device Corner in June 2025 provides a specific external recognition point; the company also announced clinical findings for EmeTerm in 2026. The small reported employee band of 1–10 and absence of disclosed funding make scale comparisons difficult. Its product breadth may address multiple consumer and clinical use cases, but the evidence and regulatory status should be evaluated product by product rather than generalized across the portfolio.

Founded in 2017, WAT Medical has developed a portfolio spanning nausea relief, migraine treatment and weight-management applications. The available milestones suggest a progression from product development toward clinical evaluation and broader market access, although they do not quantify sales, adoption or financing. In December 2024, the company announced HeadaTerm 2, describing it as an FDA-cleared device for migraine prevention using external trigeminal nerve stimulation. In January 2025, it publicized ObeEnd findings related to heart rate and perceived exercise exertion. EmeTerm then featured in reports on postoperative nausea and vomiting in November 2025 and a JAMA Surgery-published clinical trial announced February 9, 2026. Two later milestones—MOHAP manufacturing-site registration in the UAE on June 17, 2026, and U.S. recruitment for an Ohio State University chronic-nausea study announced August 17, 2026—point to continued regulatory and clinical activity. The company’s reported employee range remains 1–10, with no funding rounds or hiring news disclosed, so the pace and commercial scale of growth remain uncertain.